AtriCure, Inc. (ATRC)
-NasdaqGM 9.12 
0.07(0.76%) 4:00PM EDT
| Prev Close: | 9.19 |
|---|
| Open: | 9.20 |
|---|
| Bid: | 8.90 x 400 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 11.40 |
|---|
| Beta: | 0.15 |
|---|
| Next Earnings Date: | 2-Aug-13 |
|---|
| Day's Range: | 9.04 - 9.25 |
|---|
| 52wk Range: | 5.90 - 9.98 |
|---|
| Volume: | 58,675 |
|---|
| Avg Vol (3m): | 65,608 |
|---|
| Market Cap: | 190.89M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.46 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- AtriCure Mid-Trial Results Highly Encouragingat Seeking Alpha(Tue 12:59PM EDT)
- Promising Mid-Term Results From Thoracoscopic Ablation of Persistent Atrial Fibrillation Presented at Meeting of International Society for Minimally Invasive Cardiothoracic SurgeryBusiness Wire(Tue 2:00AM EDT)
- Positive Data for COV's SolitaireZacks(Mon, Jun 17)
- Abbott Progresses with Absorb in JapanZacks(Fri, Jun 14)
- FDA Nod for STJ's Ellipse & AssuraZacks(Thu, Jun 13)
- Symmetry Provides Dismal 2013 ViewZacks(Tue, Jun 11)
- Abbott Labs' HPV Test in CanadaZacks(Fri, May 31)
- Back to Neutral on HospiraZacks(Tue, May 28)
- ATRICURE, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Fri, May 24)
- Covidien's ENB Adopted by ACCPZacks(Thu, May 23)
- CE Mark for Abbott's Xience Xpedition 48Zacks(Wed, May 22)
- AtriCure Inc. Stock Upgraded (ATRC)at TheStreet(Wed, May 22)
- FDA Nod for COV's Advanced NellcorZacks(Tue, May 21)
- CE Mark for STJ's ILUMIEN OPTISZacks(Fri, May 17)
- Stryker Reiterated at NeutralZacks(Fri, May 17)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 2.66 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.42 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.10 |
|---|
| Mean Recommendation*: | 1.7 |
|---|
| PEG Ratio (5 yr expected): | -1.08 |
|---|
Business Summary
AtriCure, Inc., a medical device company, develops, manufactures, and sells cardiac surgical ablation systems designed to create precise lesions or scars in cardiac tissue.
View More